Anti-interleukin 6 receptor antibody treatment in rheumatic disease. - Wikidata - thesis-toulmin - TriplyDB

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

http://www.wikidata.org/entity/Q34071253

about

JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression Joint disease caused by defective gp130-mediated STAT signaling.Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain The pathological and physiological roles of IL-6 amplifier activation Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study.Directed evolution of a three-finger neurotoxin by using cDNA display yields antagonists as well as agonists of interleukin-6 receptor signaling.Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial The adrenal hormone metabolism in the immune/inflammatory reaction.Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.Synovial macrophage-osteoclast differentiation in inflammatory arthritis Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.Cytokine signal regulation and autoimmune disorders.Radiation damage and radioprotectants: new concepts in the era of molecular medicine Cytokine networks--towards new therapies for rheumatoid arthritis.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Krüppel-Like Factor 4 Is a Regulator of Proinflammatory Signaling in Fibroblast-Like Synoviocytes through Increased IL-6 Expression.Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.Therapeutic efficacy of intra-articular adrenomedullin injection in antigen-induced arthritis in rabbits.Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy.Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Interleukin-6: possible biological roles during exercise.Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Maternal serum amyloid A level as a novel marker of primary unexplained recurrent early pregnancy loss.Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.Modulatory Effects of Chrysanyhemi Flos Pharmacopuncture on Nitric-oxide (NO) Production in Murin Macrophagy Cells Tocilizumab in refractory adult Still's disease.Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.Cocoa flavonoid-enriched diet modulates systemic and intestinal immunoglobulin synthesis in adult Lewis rats.Increased levels of IL-6, IL-1β, and TNF-α in Kashin-Beck disease and rats induced by T-2 toxin and selenium deficiency.Profile of tocilizumab and its potential in the treatment of giant cell arteritis.

P2860

Q24316553-DA5D2AD1-6DC0-4E59-A4C7-7B757314AE93 Q24806131-373AC92F-344F-477D-9A5D-066926A8D2B4 Q27640083-46EA313A-635C-442C-85BB-91E90656B885 Q27690908-A7A9828F-234E-42BF-9CF9-0772ABDF85EC Q33413568-EC246869-94B7-4149-89AD-9633CCEE6B34 Q33788445-61118880-C743-4AAF-9EC6-4184D28830F8 Q33977201-08505A67-C8EF-4607-BC79-E30F03869FFB Q34456715-E1DFD759-4C0C-43B3-8F9F-50E712B1465E Q34734696-3299D37E-60FA-4BE2-8F02-7C7B41055F9C Q34795777-86AA1158-A7FB-49F9-8214-AC4F1FDE1728 Q35046446-0D983F78-918A-4AFC-8ECD-7B64BB282C6A Q35060214-6D947F84-70FC-4055-9B51-CB4B19CE4E98 Q35551058-79A02F1A-F5EA-4984-9373-8C052FE19654 Q35625089-72B6680B-2009-41D4-98EC-46C84ADC76CD Q36287536-854B498F-229F-4942-8B11-FB7007A926F7 Q36364394-FD2ED66A-4096-4055-974C-5C87411045F2 Q36577367-AEACA99B-F4C8-4A6C-8E84-6C4CE4CF36D5 Q36677277-7EA0D008-F4C4-4D63-8A74-379433D7650C Q37054152-F97D32C6-54BE-49DF-A69D-E1DE3C1F3B0F Q37089689-F47D5F52-A7A6-4BA6-9EE8-A35A49DAA5CC Q37129557-76F619C7-137A-4077-8E86-1D7F811F855C Q37161442-9B7F8D5E-C328-41D1-9113-4975649EEEFE Q37180624-09363AD8-3921-4CAC-899E-8EF47CA00A82 Q37275902-C587CD44-41FD-4863-B4C4-6A3D0BD010B1 Q37321296-D8E8A8C4-8363-402F-9295-BBA9360599E3 Q37778738-CA51A62B-3248-41D8-987E-7174A7BBF1C5 Q38044757-45AB35FE-F782-4301-9EA5-89C5AB238C17 Q38198145-5E5DD772-F10A-4F95-A0D2-8EB940209852 Q38285827-382D80BF-600C-490A-82B8-6A2B43ED00D5 Q38309810-F5543C50-29B5-4357-A7C1-A9356F803A4C Q38697262-A03A3983-616E-47C8-9376-04CB85C5E530 Q39091995-184D059A-0D25-4023-AAD8-8F5C9F1ABF17 Q39176539-42C10250-2EDF-4A55-B81B-2BC6719F9C92 Q39391539-A376C198-C4BC-46AD-A81D-B1DF42DF43FC Q40350291-47CA535D-DEF9-4455-8C2A-A9F6259BD50D Q40814798-DA831703-D1E5-4987-8F59-47BB6872A5F8 Q41360812-793C93BF-3880-427B-A3A3-A5529007AD8C Q42049190-CBFA1AE2-ECC0-4CAF-A559-320EE4598167 Q44733819-23984922-C933-482A-A236-EBAC076D2F4B Q49215677-9476F25A-3450-4E03-AE57-7FBEAD7EC23B

P2860

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

http://www.wikidata.org/entity/Q34071253

description

2000 nî lūn-bûn

@nan

2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@ast

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@en

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@nl

type

label

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@ast

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@en

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@nl

prefLabel

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@ast

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@en

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@nl

P1433

Q34071253-57C72A16-DA2E-4C63-8A4B-F715A0D0B68E

P1476

Q34071253-52A9EC08-A6FE-4E63-AC41-76E714A5E918

P2093

Q34071253-2C6BC824-67EF-4C49-9232-984C15E2D929

Q34071253-4D3FE23D-7D30-4B73-A5B0-882F218AD457

Q34071253-D4B51E34-4A9F-47A2-9B09-2EFF7444201B

P2860

Q34071253-0AE8B1A1-1FE6-44F1-9451-ECC4897BC7C4

Q34071253-1C1B6033-918C-447E-8380-0B229A320C19

Q34071253-1FE333EB-0076-47ED-A04C-D0D14AFE9AE7

Q34071253-21C1459D-8B85-4580-B25F-D47F7B1669A6

Q34071253-238C1EA0-7F76-499D-9A9D-6640C9280C95

Q34071253-2D3E590C-07C1-414B-96E4-8CDBAAAD6DAC

Q34071253-34801FCC-739A-4EB6-944E-246B3472FEB1

Q34071253-3B8A32F8-DB9E-44A7-80B3-6D9AB02470D8

Q34071253-4F4DD271-7094-4282-9603-E9C64524B122

Q34071253-60A4EDB9-658C-4FBB-98E2-7A30C67C6CE0

P304

Q34071253-91997AF0-D90C-482E-92F3-1A65C55A6423

P31

Q34071253-5B0EC64D-D50D-4E67-993E-B22446B37A40

P356

Q34071253-721CAF6B-CDF6-4EDA-B232-15E4FC509B8A

P407

Q34071253-96C47614-6096-486C-B253-92887107AFAB

P478

Q34071253-7B92EA09-8DEC-4D21-BE72-53D94C88AA54

P577

Q34071253-E40CE702-AC77-4830-A0DF-19220A4EC92D

P5875

Q34071253-093EF7B7-1908-49BF-938A-5A6F00C5B146

P698

Q34071253-28BE49D1-AA97-40DF-99E6-5F091053F9C3

P921

Q34071253-5f8de4bf-8d05-452b-a5f9-00031cd33851

Q34071253-7D822DAA-AB5F-4496-A836-56359BB20169

P932

Q34071253-AA2166D3-569D-4CA3-87B9-802C4D7FDB9B

P356

ARD.59.SUPPL_1.I21

P1433

Annals of the Rheumatic Diseases

P1476

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

@en

P2093

Kishimoto T

http://www.w3.org/2001/XMLSchema#string

Nishimoto N

http://www.w3.org/2001/XMLSchema#string

Yoshizaki K

http://www.w3.org/2001/XMLSchema#string

P2860

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Interleukin 2-dependent and interleukin 2-independent pathways of regulation of thymocyte function by interleukin 6.

Localized mediastinal lymphnode hyperplasia resembling thymoma.

P304

i21-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.59.SUPPL_1.I21

http://www.w3.org/2001/XMLSchema#string

P407

P478

59 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2000-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277372558

http://www.w3.org/2001/XMLSchema#string

P698

11053081

http://www.w3.org/2001/XMLSchema#string

P921

P932

1766618

http://www.w3.org/2001/XMLSchema#string